Institute of Rheumatology

Recent papers from Institute of Rheumatology

1. Cancer in systemic sclerosis: clinical associations and prognostic impact from the EUSTAR registryArthritis & Rheumatology · 2026
2. Hereditary Renal Hypouricemia Caused by a Novel SLC2A9 Variant: Functional Characterization and Systematic Literature ReviewBratislavské lekárske listy/Bratislava medical journal · 2026
3. Genetic Architecture of Idiopathic Inflammatory Myopathies From Meta‐AnalysesArthritis & Rheumatology · 2024
4. Efficacy and safety of filgotinib in patients with active radiographic and nonradiographic axial spondyloarthritis: results from OLINGUITO, a phase 3 trial consisting of 2 randomised, placebo-controlled, double-blind, parallel-group studiesAnnals of the Rheumatic Diseases · 2026
5. Multimodal Immune Profiling in Thyroid Eye Disease 2253789The Journal of Immunology · 2026
6. Defining and validating a high specificity MRI cut-off for the radiographic part of the modified New York criteria in patients with axial spondyloarthritisArthritis Research & Therapy · 2026
7. Development of a Disease Activity Index for the Assessment of VEXAS Syndrome ( VEXAS ‐ DAI )Arthritis Care & Research · 2026
8. Case Report: Immune checkpoint inhibitor-induced IgG4-related disease mimicking renal metastatic progression: successful steroid-sparing management with rituximabFrontiers in Immunology · 2026
9. Alterations in systemic and skeletal muscle myostatin regulation are most prominent at disease onset and associate with muscle-related outcomes in idiopathic inflammatory myopathiesArthritis Research & Therapy · 2026
10. Early to mid-Holocene climate oscillations and cultural shifts in the eastern MediterraneanQuaternary Science Reviews · 2026
11. Association of inflammation and serum adipocytokines with depression and anxiety burden in axial spondyloarthritisScientific Reports · 2026
12. Impact of cardiometabolic comorbidities on clinical characteristics, prescription patterns and retention rate of first b/tsDMARD treatment in 5299 European real-world patients with psoriatic arthritisRMD Open · 2026
13. Beyond screening for pulmonary arterial hypertension: The DETECT score is a potential promising prediction tool for all-cause mortality in systemic sclerosis: Analysis from the EUSTAR databaseJournal of Autoimmunity · 2026
14. Cellular miRNA-31 and miRNA-125b as predictors of remission and major disease improvement in patients with early rheumatoid arthritisScientific Reports · 2026
15. Machine Learning to Predict Remission Between Six and 24 Months in Rheumatoid Arthritis: Insights from the JAK‐pot CollaborationArthritis & Rheumatology · 2026
16. A Phase 3 Trial of Brepocitinib in DermatomyositisNew England Journal of Medicine · 2026
17. Coding systems and monitoring practices across the ERN ReCONNET: insights from a comprehensive survey and unmet needsOrphanet Journal of Rare Diseases · 2026
18. Interlaboratory variability in laboratory testing and reporting of myositis autoantibodiesJournal of Autoimmunity · 2026
19. Risk score for early mortality to stratify for intensive SSc therapy in the EUSTAR network: the RESIST scoreAnnals of the Rheumatic Diseases · 2026
20. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 updateAnnals of the Rheumatic Diseases · 2026